Janus Henderson Group PLC Akero Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

$194 Billion
Q2 2025

A detailed history of Janus Henderson Group PLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 6,738,556 shares of AKRO stock, worth $324 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

6,738,556

Previous 7,068,648 4.67%

Holding current value

$324 Million

Previous $286 Million 25.66%

% of portfolio

0.19%

Previous 0.16%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$34.04 - $56.28 $11.2 Million - $18.6 Million	-330,092 Reduced 4.67%	6,738,556 $360 Million
Q1 2025 May 15, 2025	BUY	$21.87 - $57.56 $22.6 Million - $59.5 Million	1,034,409 Added 17.14%	7,068,648 $286 Million
Q4 2024 Feb 14, 2025	SELL	$26.75 - $35.28 $27.9 Million - $36.8 Million	-1,043,239 Reduced 14.74%	6,034,239 $168 Million
Q3 2024 Nov 14, 2024	BUY	$21.45 - $29.34 $4.32 Million - $5.9 Million	201,225 Added 2.93%	7,077,478 $203 Million
Q2 2024 Aug 14, 2024	BUY	$18.31 - $24.62 $13.8 Million - $18.6 Million	754,283 Added 12.32%	6,876,253 $161 Million
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $32.2 Million - $56.6 Million	1,815,569 Added 42.16%	6,121,970 $155 Million
Q4 2023 Feb 14, 2024	SELL	$11.38 - $50.33 $2.05 Million - $9.08 Million	-180,325 Reduced 4.02%	4,306,401 $101 Million
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $2.54 Million - $3.22 Million	61,607 Added 1.39%	4,486,726 $227 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $22.6 Million - $34.9 Million	613,443 Added 16.09%	4,425,119 $207 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $17.6 Million - $23.7 Million	471,502 Added 14.12%	3,811,676 $146 Million
Q4 2022 Feb 14, 2023	SELL	$33.44 - $54.8 $31.3 Million - $51.3 Million	-935,285 Reduced 21.88%	3,340,174 $183 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $12.3 Million - $41.1 Million	1,207,147 Added 39.34%	4,275,459 $146 Million
Q2 2022 Aug 15, 2022	SELL	$8.0 - $15.01 $2.4 Million - $4.51 Million	-300,350 Reduced 8.92%	3,068,312 $29 Million
Q1 2022 May 16, 2022	BUY	$12.97 - $22.26 $2.66 Million - $4.56 Million	205,040 Added 6.48%	3,368,662 $47.8 Million
Q4 2021 Feb 14, 2022	SELL	$19.87 - $26.24 $1.42 Million - $1.87 Million	-71,365 Reduced 2.21%	3,163,622 $66.9 Million
Q3 2021 Nov 16, 2021	SELL	$18.65 - $25.46 $4.71 Million - $6.43 Million	-252,508 Reduced 7.24%	3,234,987 $72.3 Million
Q2 2021 Aug 16, 2021	BUY	$24.81 - $32.35 $119,832 - $156,250	4,830 Added 0.14%	3,487,495 $86.5 Million
Q1 2021 May 17, 2021	SELL	$24.04 - $34.19 $258,526 - $367,679	-10,754 Reduced 0.31%	3,482,665 $101 Million
Q4 2020 Feb 16, 2021	SELL	$25.12 - $29.89 $1.06 Million - $1.26 Million	-42,036 Reduced 1.19%	3,493,419 $90.1 Million
Q3 2020 Nov 16, 2020	BUY	$30.79 - $39.92 $24.5 Million - $31.8 Million	796,937 Added 29.1%	3,535,455 $109 Million
Q2 2020 Aug 14, 2020	SELL	$19.25 - $26.76 $544,813 - $757,361	-28,302 Reduced 1.02%	2,738,518 $68.2 Million
Q1 2020 May 14, 2020	BUY	$12.8 - $27.05 $4.57 Million - $9.66 Million	357,287 Added 14.83%	2,766,820 $58.7 Million
Q4 2019 Feb 18, 2020	BUY	$17.37 - $27.27 $6.59 Million - $10.3 Million	379,505 Added 18.69%	2,409,533 $53.5 Million
Q3 2019 Nov 14, 2019	BUY	$16.89 - $29.88 $21.4 Million - $37.9 Million	1,268,875 Added 166.7%	2,030,028 $46.2 Million
Q2 2019 Jul 31, 2019	BUY	$18.08 - $19.83 $13.8 Million - $15.1 Million	761,153 New	761,153 $14.6 Million

Others Institutions Holding AKRO

# of Institutions

296

Shares Held

92.2M

Call Options Held

1.72M

Put Options Held

901K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.23B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Akero Therapeutics, Inc. Transaction History